Cost-Effectiveness Analysis of Crohn’s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-2027
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Cost-Effectiveness Analysis of Crohn’s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist ; volume:36 ; number:7 ; day:17 ; month:4 ; year:2018 ; pages:853-865 ; date:7.2018
PharmacoEconomics ; 36, Heft 7 (17.4.2018), 853-865, 7.2018
- Urheber
-
Holko, Przemysław
- Beteiligte Personen und Organisationen
-
Kawalec, Paweł
Pilc, Andrzej
SpringerLink (Online service)
- DOI
-
10.1007/s40273-018-0653-2
- URN
-
urn:nbn:de:101:1-2018082123133013772692
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:36 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Holko, Przemysław
- Kawalec, Paweł
- Pilc, Andrzej
- SpringerLink (Online service)
Ähnliche Objekte (12)
Comparison of surgery rates in biologic-naïve patients with Crohn’s disease treated with vedolizumab or ustekinumab: findings from SOJOURN
Posterior Reversible Encephalopathy Syndrome following Ustekinumab Induction for Crohn’s Disease
Elderly-onset Crohn’s disease remarkably responsive to ustekinumab: a case report
Successful Drug Desensitization to Ustekinumab in a Patient with Crohn’s Disease
Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn’s Disease
Ustekinumab inhibits T follicular helper cell differentiation in patients with Crohn’s disease
Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden
Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn’s Disease
Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn’s disease
Pustular Rash in Crohn’s Patient on Ustekinumab Raises Concern for Drug-Induced Paradoxical Psoriasis
Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn’s disease patients over three years
Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn’s Disease Patients Stratified by Age
Comparison of surgery rates in biologic-naïve patients with Crohn’s disease treated with vedolizumab or ustekinumab: findings from SOJOURN
Posterior Reversible Encephalopathy Syndrome following Ustekinumab Induction for Crohn’s Disease
Elderly-onset Crohn’s disease remarkably responsive to ustekinumab: a case report
Successful Drug Desensitization to Ustekinumab in a Patient with Crohn’s Disease
Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn’s Disease
Ustekinumab inhibits T follicular helper cell differentiation in patients with Crohn’s disease
Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden
Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn’s Disease
Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn’s disease
Pustular Rash in Crohn’s Patient on Ustekinumab Raises Concern for Drug-Induced Paradoxical Psoriasis
Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn’s disease patients over three years
Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn’s Disease Patients Stratified by Age
Comparison of surgery rates in biologic-naïve patients with Crohn’s disease treated with vedolizumab or ustekinumab: findings from SOJOURN
Posterior Reversible Encephalopathy Syndrome following Ustekinumab Induction for Crohn’s Disease
Elderly-onset Crohn’s disease remarkably responsive to ustekinumab: a case report
Successful Drug Desensitization to Ustekinumab in a Patient with Crohn’s Disease
Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn’s Disease
Ustekinumab inhibits T follicular helper cell differentiation in patients with Crohn’s disease
Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden
Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn’s Disease
Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn’s disease
Pustular Rash in Crohn’s Patient on Ustekinumab Raises Concern for Drug-Induced Paradoxical Psoriasis
Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn’s disease patients over three years